Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro Sampling

Glioblastoma, a deadly brain tumor, shows limited response to standard therapies like temozolomide (TMZ). Recent findings from the REGOMA trial underscore a significant survival improvement offered by Regorafenib (REGO) in recurrent glioblastoma. Our study aimed to propose a 3D ex vivo drug response...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Mariangela Morelli, Francesca Lessi, Sara Franceschi, Gianmarco Ferri, Manuel Giacomarra, Michele Menicagli, Carlo Gambacciani, Francesco Pieri, Francesco Pasqualetti, Nicola Montemurro, Paolo Aretini, Orazio Santo Santonocito, Anna Luisa Di Stefano, Chiara Maria Mazzanti
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2024-03-01
Saila:	Cells
Gaiak:	glioblastoma NADP(H) FLIM Regorafenib drug response organoids
Sarrera elektronikoa:	https://www.mdpi.com/2073-4409/13/6/487
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!